This site is intended for health professionals only
Sunday 15 July 2018
Share |

Topic: anticoagulation

November 25, 2015
Critical care providers can determine their patients’ coagulation status quickly and accurately, allowing them to make immediate, informed decisions

Roche announced that it has launched the CoaguChek Pro II system in countries accepting the CE Mark.1 CoaguChek Pro II combines two tests in a single device – the activated partial thromboplastin time (aPTT) test and the prothrombin time (PT) test with extended claims – for greater insight into patients’ coagulation status in acute care settings, such as emergency rooms, operating rooms and intensive care units, or anticoagulation clinics.

March 10, 2015
NICE draft guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots In draft guidance published, NICE has recommended the anti-blood clotting drug apixaban as an option for treating and preventing venous thromboembolism in adults. VTE is a term used to describe deep vein thrombosis (DVT) and pulmonary embolism (PE). When a blood clot forms in one of the deep veins in the leg, thigh, pelvis or arm it is known as a DVT. If part of the blood clot comes loose it can be carried in the blood to another part of the body where it can cause problems. If the blood clot reaches the lungs (PE), it can be fatal.

VTE is a term used to describe deep vein thrombosis (DVT) and pulmonary embolism (PE). When a blood clot forms in one of the deep veins in the leg, thigh, pelvis or arm it is known as a DVT. If part of the blood clot comes loose it can be carried in the blood to another part of the body where it can cause problems. If the blood clot reaches the lungs (PE), it can be fatal.

 

November 20, 2012
Bayer HealthCare’s oral anticoagulant Xarelto® (rivaroxaban) has been approved by the European Commission (EC) for the treatment of pulmonary embolism (PE) and the prevention of recurrent deep vein thrombosis (DVT) and PE in adults.
Bayer HealthCare's oral anticoagulant Xarelto® (rivaroxaban) has been approved by the European Commission (EC) for the treatment of pulmonary embolism (PE) and the prevention of recurrent deep vein thrombosis (DVT) and PE in adults. This approval makes rivaroxaban the only novel oral anticoagulant approved in this indication in the EU.